What Imraldi Treats: Main Uses and Benefits

Imraldi is a prescription medicine intended to help manage the symptoms associated with various chronic inflammatory disorders. Its therapeutic goal is to help address the underlying inflammation involved in these conditions.

This medicine is authorized for a number of specific indications. These include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

This medicine is designed to help moderate symptoms such as joint pain, stiffness, swelling, and skin lesions. The clinical decision to use Imraldi often relates to patients with severe or progressively worsening conditions, or when other treatment options have not provided a suitable response.

---

Quick Fact: Supports Management of Inflammation

Imraldi is used to help address the inflammatory process in various chronic conditions, aiming to support symptom management.

Regulatory References

1. European Medicines Agency (EMA) therapeutic overview

Imraldi's eligibility is determined by specific regulatory criteria relating to age, current health status, and pre-existing conditions.

Populations Excluded from Use

The medicine is contraindicated and must not be used by patients who have a known hypersensitivity to adalimumab or any of its excipients. Additionally, it is excluded for patients with active tuberculosis or other severe infections, such as sepsis. Patients with moderate to severe heart failure (NYHA Class III/IV) are also formally excluded from treatment.

Age-Based and Conditional Eligibility

Population Group	Regulatory Status	Status Detail
Adults	Generally Approved	Authorized for use across all labeled indications.
Pediatric Patients	Approved, Age-Restricted	Eligibility starts at 2 years of age for conditions like uveitis, or at 4 to 6 years of age for other indications (e.g., plaque psoriasis, Crohn’s disease). Use in infants under 2 years of age is not established.
Infection Status	Restricted/Conditional	Treatment must not be started during an active infection. Patients with latent tuberculosis must receive prophylactic treatment before Imraldi is initiated.
Reproductive Status	Conditional	Women of childbearing potential must use effective contraception during therapy and for 5 months after the final dose.
Organ Function	Not Established	No dose recommendations can be made for patients with impaired renal and/or hepatic function as clinical data in these populations are insufficient.

Interactions with other medicines and products

Imraldi (adalimumab biosimilar) has documented interactions primarily relating to its effects on the immune system and its drug levels in the body.

Contraindicated and Non-Recommended Combinations

Combination therapy with certain other biological agents is not recommended due to a documented increased risk of serious infection without added clinical benefit.

Classification	Interacting Substance/Class	Regulatory Recommendation
Contraindicated	Live Vaccines	Avoid during treatment
Non-Recommended	Abatacept, Anakinra	Use discouraged (increased infection risk)

Pharmacokinetic Interaction

Methotrexate, a conventional Disease-Modifying Anti-Rheumatic Drug (DMARD), has been documented to interact with adalimumab's clearance. Concomitant use with methotrexate reduces the apparent clearance of adalimumab, resulting in higher serum concentrations of the drug.

General Interaction Context

Concomitant use of Imraldi with other systemic immunosuppressive agents may also increase the risk of serious infection. Patients should ensure all appropriate immunizations are complete, especially live vaccines, before initiating treatment. The interaction profile is largely structured around preventing additive immunosuppression and managing the change in drug exposure caused by methotrexate.

Targeted Neutralization of TNF-alpha

Imraldi is a humanized monoclonal antibody designed to act as a selective neutralizer of the central inflammatory cytokine, Tumor Necrosis Factor alpha ( TNF-alpha). The drug binds with high affinity to both the soluble and transmembrane forms of TNF-alpha, physically blocking the cytokine from activating its target receptors ( TNFR1 and TNFR2) on immune and tissue cells.

Interruption of Downstream Inflammatory Cascades

By blocking the TNF-alpha signal, the drug functionally suppresses the resulting intracellular signaling cascade, notably the NF-kappa B pathway. This mechanism reduces the cell's ability to produce and release numerous secondary proinflammatory mediators (like IL-6) and adhesion molecules, which are necessary for the sustained, chronic inflammatory response.

Modulation of Systemic Tissue Destruction

The suppression of this key inflammatory signaling loop results in diminished biological activity implicated in tissue remodeling. This physiological consequence includes the inhibition of RANKL-mediated activation of osteoclasts, the cells responsible for bone erosion, thereby influencing the physiological processes that lead to structural remodeling.

Imraldi (adalimumab) is administered as an injection under the skin (subcutaneous), using either a pre-filled syringe or a pre-filled pen. The dose and frequency are determined by your healthcare provider based on your specific condition, which may be every week or every other week.

Preparation and Injection

Imraldi must be stored in the refrigerator. Before injection, remove the syringe or pen from the refrigerator and let it warm up to room temperature for about 15 to 30 minutes. Do not remove the needle cap or warm the medicine using any heat source (such as a microwave or hot water).

1. Check the Medicine: Visually inspect the solution before use. It should be clear and colorless to pale yellow. Do not use the injection if the liquid is cloudy, discolored, or contains flakes or particles, or if the expiration date has passed.
2. Choose the Site: The recommended injection sites are the front of your thighs or the abdomen, at least two inches away from the navel. You must rotate the injection site with each dose to help prevent skin issues. Avoid injecting into areas where the skin is red, bruised, tender, hard, or scarred.
3. Clean the Site: Clean the chosen injection area with an alcohol swab and allow the skin to dry completely.
4. Inject: Inject the full amount of medicine exactly as you were trained by your healthcare professional. The first injection should be performed under the supervision of a healthcare provider. After injection, dispose of the used pen or syringe immediately in a sharps disposal container. Do not rub the injection site afterward.

Research evidence / Overview of studies for Imraldi

Evidence for use in Rheumatoid Arthritis

Imraldi was studied for use in adults with rheumatoid arthritis, a condition characterized by fluctuating or episodic manifestations often leading to outcomes related to physical discomfort and functional limitations. Research examined how outcomes related to systemic or functional imbalance evolved in individuals over defined time intervals. Studies exploring Imraldi involved comparisons against a placebo or other therapies.

Research monitored how symptoms evolved, tracking patient-reported outcomes and changes in joint measurements. Findings describe patterns observed in the studies. However, data for certain groups remain insufficient, and comparative evidence is lacking to fully understand how Imraldi compares to every other treatment option available. Research does not determine whether an individual will respond similarly to the group findings.

Evidence for use in Psoriasis and Psoriatic Arthritis

Imraldi was evaluated in research for the management of moderate to severe plaque psoriasis and psoriatic arthritis, both conditions involving periods of heightened symptoms. Studies often focused on skin involvement and joint outcomes linked to inflammatory or irritative states. Studies report how symptoms evolved, and findings may suggest patterns related to changes in skin condition and physical discomfort.

It is important to understand that the results apply only to the populations studied. The follow-up durations were limited in many of the initial trials, and certainty remains low in areas where findings were inconsistent across studies.

---

Long-term studies and follow-up

Research has also explored the effects of Imraldi beyond the initial short-term phases, aiming to gather information about sustained changes in outcomes reflecting daily functioning. While long-term data contribute to the broader evidence landscape, it is crucial to note that long-term effects are not fully established. Evidence is limited when considering very long-term use, and data are still emerging from ongoing observational settings.

Evidence in special populations

Imraldi was studied for use in children with certain forms of juvenile idiopathic arthritis. The sample sizes were modest in some of these specialized studies. Research has also explored use in older adults and individuals with other co-existing medical conditions. For these groups, evidence is limited and data for certain groups remain insufficient.

What is still uncertain about Imraldi

Despite the research that has been studied for Imraldi, important areas remain where the evidence is not yet complete. Long-term effects are not fully established, and research is ongoing. For example, findings were mixed in certain subgroup analyses, and the comparative evidence is lacking in every scenario. Research provides context but not individual predictions about how a person may respond to treatment.

Common questions about Imraldi (FAQ)

Q: What is the main difference between Imraldi and its reference medicine, Humira?

Imraldi is a biosimilar medicine that has been approved based on having demonstrated comparable efficacy and safety to the reference product, Humira. A key difference between them may relate to the inactive ingredients (excipients) used in the formulation or the specific design of the injection device itself. Regulatory information confirms that both contain the same active substance, adalimumab.

Q: Can Imraldi be taken by people who are also taking methotrexate?

Adalimumab is officially indicated for use alone or in combination with methotrexate. Studies have shown that methotrexate can reduce the clearance of adalimumab, meaning the drug may remain at higher concentrations in the body. Information regarding the use of Imraldi alongside other medicines is best reviewed with a healthcare provider.

Q: What should I know about combining Imraldi with live vaccines?

Official regulatory documents state that live vaccines must be avoided while a person is undergoing treatment with Imraldi. This restriction is due to the medicine's effect on the immune system. Furthermore, an infant who was exposed to adalimumab during pregnancy should not receive live vaccines for a specific duration after birth.

Q: Can a person travel with Imraldi?

Regulatory storage information indicates that while Imraldi is usually stored in the refrigerator, it may be stored at a temperature up to 25 C for a single period of up to 31 days. This stability information provides the parameters for temporary storage conditions, which may be relevant when traveling. Regulatory storage information notes that if the medicine has been stored at room temperature, it should not be returned to the refrigerator.

Q: What are the serious safety warnings associated with Imraldi?

Major safety warnings documented in the official labeling relate primarily to the potential for serious infections and the risk of malignancies (cancers). Serious infections mentioned include tuberculosis (TB) and invasive fungal infections. Patients are monitored closely for signs of these risks throughout therapy.

Q: Can a person combine Imraldi with nonsteroidal anti-inflammatory drugs (NSAIDs)?

The official product labeling for adalimumab does not list a specific prohibition against the use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Adalimumab is known to be used alongside non-biologic disease-modifying anti-rheumatic drugs (DMARDs) and other standard treatments.

Q: How often is Imraldi typically administered?

The most common dosing schedule involves administering the medicine every other week. However, for certain conditions or if a person shows an insufficient response to treatment, the schedule may be changed to require administration every week.

Q: What type of monitoring is necessary while a patient is using Imraldi?

Patients must be continuously monitored for signs and symptoms of infection throughout the entire course of therapy. Before treatment begins, mandatory screening for Tuberculosis (TB) and Hepatitis B Virus (HBV) infection is required. Monitoring for HBV carriers must also continue during and after therapy.

Q: What if a user is allergic to latex; is this a concern with the Imraldi injector?

Official product information notes that specific components of the injection device for adalimumab biosimilars may contain latex. Individuals with a known latex allergy should review the specific components of their prescribed Imraldi device.

Q: Why do doctors prescribe Imraldi for conditions like rheumatoid arthritis?

Imraldi is prescribed because it functions as an anti-TNF-alpha agent, which helps reduce the signs and symptoms of chronic inflammatory diseases like rheumatoid arthritis. By reducing systemic inflammation, the medicine also works to slow down the damage to the cartilage and bone of the joints caused by the disease.

Q: How long does it usually take before a person notices any effects from Imraldi?

Based on clinical trial data found in regulatory documents, a person generally achieves a clinical response within 12 weeks of starting treatment. Official information indicates that if a person has not responded within this timeframe, the continuation of therapy may be reassessed.

Q: What happens if I forget a dose of Imraldi?

Official patient information advises that if a dose is missed, the patient should inject the next dose as soon as they remember. It is important not to double the next dose to make up for the missed one. Confirmation of how to resume the regular schedule is a topic for discussion with a healthcare provider.

Q: What are the general guidelines for using alcohol while on Imraldi?

Official patient information states that generally, there are no known direct risks associated with consuming alcohol while taking adalimumab. You can usually eat and drink normally. Any specific concerns regarding alcohol use can be reviewed with a healthcare provider.

Q: If I have mild psoriasis, is Imraldi a treatment option?

Imraldi is officially approved and indicated for treating moderate to severe plaque psoriasis in adults. For children and adolescents, it is indicated for severe chronic plaque psoriasis. It is not generally indicated for mild forms of the condition.

Q: Are there any long-term research studies about Imraldi’s use?

Regulatory frameworks require the collection of ongoing safety and effectiveness data, and research has explored sustained changes in patient outcomes for adalimumab. This long-term follow-up contributes to the broader evidence base for the medicine.

Q: Can Imraldi be used during pregnancy, according to official documents?

Official patient information states that the medicine can be taken during pregnancy if the treating physician considers it necessary to maintain the patient's health. Women of childbearing potential are advised to use effective contraception during therapy and for five months after the final dose.

Q: What is the recommended approach if a person develops a fever while on Imraldi?

Official warnings describe that contact with a physician is necessary if a person develops signs of infection. These signs can include a persistent cough, weight loss, listlessness, or a mild fever. A fever can be an early symptom of a serious infection like tuberculosis or sepsis.

Q: Can the effectiveness of Imraldi wear off over time?

Clinical experience has included the observation of patients who experience a loss of response to adalimumab over time. Regulatory limitations of use note that effectiveness has not been fully established in patients who have lost response to other TNF blockers.

Q: Is there evidence for Imraldi being used to treat uveitis?

Yes, Imraldi is officially approved and indicated for the treatment of non-infectious uveitis in adults. It is also indicated for use in children with chronic non-infectious anterior uveitis, with eligibility starting from two years of age depending on the case.

Q: Are there any specific dietary restrictions to follow while on Imraldi?

Official patient information states that a person can eat and drink normally while taking adalimumab. There are generally no specific dietary restrictions mentioned in the regulatory documents for this medicine.

Q: Is Imraldi approved for treating ulcerative colitis?

Yes, Imraldi is officially indicated for the treatment of moderate to severe ulcerative colitis in adults. It is also approved for pediatric patients with moderate to severe ulcerative colitis, with eligibility starting from five years of age.

Q: Does Imraldi affect a person's liver function?

Official regulatory documents list liver injury, including liver failure, as a documented adverse reaction associated with adalimumab use. Because of this risk, patients must be monitored for symptoms that may suggest liver problems.

Q: Are there known interactions between Imraldi and herbal supplements?

Official patient information advises individuals to inform their doctor of all medicines, vitamins, and herbal supplements they are taking. General patient information states that no vitamin or other nutrient interactions have been reported with adalimumab.

Q: Does taking Imraldi increase the risk of developing certain types of cancer, based on official information?

Official documents state that the incidence of malignancies was greater in adalimumab-treated patients than in controls. There is an increased risk of developing lymphoma and non-melanoma skin cancer associated with the medicine.

Q: What are the specific conditions Imraldi is approved to treat?

The medicine is officially indicated for a range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

Q: Are there any restrictions on sun exposure while using Imraldi?

While a direct restriction is not always stated, the official label does disclose an increased risk of non-melanoma skin cancer. Patients should be aware of this specific risk, as such cancers are often linked to ultraviolet (UV) exposure.

Q: How is Imraldi excreted from the body?

The medicine is a large protein molecule, and its elimination from the body is detailed in the Pharmacokinetics section of official documents. It is typically cleared through catabolism (the body's natural breakdown of proteins) and the activity of the reticuloendothelial system, rather than through the kidneys or urine.

How to Store and Dispose of Imraldi

Imraldi (adalimumab) requires specific storage and handling to maintain its stability, as outlined in official regulatory documents.

Storage Requirement	Official Instruction
Primary Storage	Store in the refrigerator between 2 C and 8 C.
Prohibited Environment	Do not freeze. Do not use if the medicine has been frozen.
Light Protection	Keep the pre-filled pen/syringe in the original outer carton to protect from light.
Room Temperature Stability	May be stored at a temperature up to 25 C for a single period of up to 31 days.
Disposal of Used Device	Used pens or syringes must be placed immediately into a sharps container.
Disposal of Unused Medicine	Unused or expired medicine must not be thrown away with household waste or flushed down the toilet. Return unused product to a pharmacist or follow local waste disposal regulations.
Child Safety	Keep the medicine out of the sight and reach of children.